|
|
7DW8-5 |
|
Vaxjo ID |
143 |
|
Vaccine Adjuvant Name |
7DW8-5 |
|
Adjuvant VO ID |
VO_0005515
|
|
Description |
small molecule, synthetic derivative of natural compound (galactosylceramide) that binds to CD1D molecule to induce th1 response |
|
Stage of Development |
Research |
|
Location Licensed |
United States |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Monkey |
|
Components |
alpha-GalCer with a shorter fatty acyl chain with a fluorinated benzene ring at the end |
|
Function |
Type: synthetic vaccine adjuvant. Induces Th1-biased immune profile. CD1d-restricted iNKT cell activation |
| References |
(Tsuji, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=67]
Li et al., 2017: Li X, Huang J, Kawamura A, Funakoshi R, Porcelli SA, Tsuji M. Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect. Vaccine. 2017; 35(24); 3171-3177. [PubMed: 28483194].
|
|
